CL2012000585A1 - Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante. - Google Patents

Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante.

Info

Publication number
CL2012000585A1
CL2012000585A1 CL2012000585A CL2012000585A CL2012000585A1 CL 2012000585 A1 CL2012000585 A1 CL 2012000585A1 CL 2012000585 A CL2012000585 A CL 2012000585A CL 2012000585 A CL2012000585 A CL 2012000585A CL 2012000585 A1 CL2012000585 A1 CL 2012000585A1
Authority
CL
Chile
Prior art keywords
aluminum
tlr7
immunogenic composition
composition
antigen
Prior art date
Application number
CL2012000585A
Other languages
English (en)
Inventor
Manmoham Singh
Siddhartha Jain
David Skibinski
Francesco Doro
Simona Cianetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012000585A1 publication Critical patent/CL2012000585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN INMUNOGENICA QUE COMPRENDE (I) UN COMPUESTO DE FÓRMULA (I), Ó UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, (II) UN ANTIGENO, Y (III) UN ADYUVANTE QUE CONTIENE ALUMINIO: EN DONDE EL ADYUVANTE QUE CONTIENE ALUMINIO ES SELECCIONADO DE HIDRÓXIDO DE ALUMINIO, OXIHIDROXIDO DE ALUMINIO, Y HIDROXIFOSFATO DE ALUMINIO: Y EN DONDE EL COMPUESTO DE FÓRMULA (I) ES UN AGONISTA DE TLR7; UN MÉTODO PARA MEJORAR SU EFECTIVIDAD, Y SU USO PARA AUMENTAR LA RESPUESTA INMUNE.
CL2012000585A 2009-09-02 2012-03-02 Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante. CL2012000585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23915609P 2009-09-02 2009-09-02

Publications (1)

Publication Number Publication Date
CL2012000585A1 true CL2012000585A1 (es) 2012-09-14

Family

ID=43415378

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000585A CL2012000585A1 (es) 2009-09-02 2012-03-02 Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante.

Country Status (15)

Country Link
US (1) US9950062B2 (es)
EP (1) EP2459216B1 (es)
JP (1) JP5988492B2 (es)
CN (1) CN102844047B (es)
AU (1) AU2010290896B2 (es)
BR (1) BR112012004806B8 (es)
CA (1) CA2772916C (es)
CL (1) CL2012000585A1 (es)
DK (1) DK2459216T3 (es)
EA (1) EA026401B1 (es)
ES (1) ES2443952T3 (es)
MX (1) MX2012002723A (es)
NZ (1) NZ598654A (es)
SG (1) SG178954A1 (es)
WO (1) WO2011027222A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
US12037355B2 (en) 2015-11-06 2024-07-16 Adjuvance Technologies, Inc. Triterpene saponin analogues

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
KR20140030132A (ko) 2011-01-10 2014-03-11 클리브랜드 바이오랩스, 아이엔씨. 암을 치료하기 위한 톨-유사 수용체 효능제의 용도
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
EP2502631A1 (en) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
CN103649336A (zh) 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CN104093418A (zh) * 2011-09-01 2014-10-08 诺华股份有限公司 金黄色葡萄球菌抗原的含佐剂制剂
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
LT2822947T (lt) * 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
CN104582726A (zh) * 2012-03-07 2015-04-29 诺华股份有限公司 狂犬病病毒免疫原的含佐剂制剂
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CN103566369B (zh) * 2012-08-01 2015-11-25 中国医学科学院肿瘤医院 一种在慢性乙肝病毒感染状态下诱导机体产生特异性免疫的乙肝疫苗
WO2014033190A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CN109045294A (zh) * 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
EP3798229A1 (en) 2014-03-25 2021-03-31 Yale University Uses of parasite macrophage migration inhibitory factors
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
JP6940916B2 (ja) 2014-07-30 2021-09-29 ゲノム プロテクション，インコーポレイテッド フラジェリン組成物および使用
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
MX2018014086A (es) * 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
WO2018175854A1 (en) * 2017-03-23 2018-09-27 The Children's Medical Center Corporation Methods and compositions relating to adjuvants
CN107167524A (zh) * 2017-03-27 2017-09-15 万全万特制药（厦门）有限公司 气相色谱法分离检测阿立哌唑有关物质的方法
EP3612550B1 (en) 2017-04-19 2025-06-18 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
CN108218982A (zh) * 2018-02-02 2018-06-29 暨南大学 人巨细胞病毒anti-UL148多克隆抗体及其制备方法与应用
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
CN112770742A (zh) 2018-07-27 2021-05-07 阿佩塔生物科学有限公司 用于治疗蠕形螨引起的眼部和面部疾病的多杀菌素制剂
CN109191326B (zh) * 2018-08-23 2021-11-30 东北大学 基于攻击方视角的配电网cps相依存系统网络攻击风险评估方法
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
US20220096526A1 (en) * 2019-01-22 2022-03-31 Tufts Medical Center, Inc. Methods and compositions for the treatment and prevention of ocular diseases and conditions
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
WO2022011014A1 (en) * 2020-07-09 2022-01-13 Exocure Biosciences, Inc. Bacteria-derived vesicles and use thereof for generating immune response to sars-cov-2
JP2023549815A (ja) 2020-11-13 2023-11-29 アイコサバックス， インコーポレイテッド メタニューモウイルスのためのタンパク質ベースのナノ粒子ワクチン
CN114053410A (zh) * 2021-11-24 2022-02-18 肖军宏 一种治疗冠状病毒感染及其相关症状的大蒜素制剂
CN114539426B (zh) * 2022-03-02 2023-07-07 山东仙普爱瑞科技股份有限公司 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法
JP2025517362A (ja) 2022-05-17 2025-06-05 アイコサバックス， インコーポレイテッド パラミクソウイルス用の多価ワクチン及びその使用
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN117003898B (zh) * 2023-09-27 2023-12-29 贝格探索(成都)科技有限公司 一种lhrh4-crm197-lf多聚重组蛋白及其制备方法和应用
WO2025077785A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US5059258A (en) 1989-08-23 1991-10-22 Aluminum Company Of America Phosphonic/phosphinic acid bonded to aluminum hydroxide layer
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
CA2205406C (en) 1994-11-24 2008-02-05 F. Hoffmann-La Roche Ag Novel benzyl pyrimidines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
EP0907738A1 (en) 1996-04-02 1999-04-14 Smithkline Beecham Corporation Novel compounds
EP0914330A4 (en) 1996-05-14 2002-01-09 Smithkline Beecham Corp NEW TYPE COMPOUNDS
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JP2001514001A (ja) 1997-08-21 2001-09-11 オランダ国 グラム陰性粘膜細菌の新規突然変異株及びそのワクチンにおける応用
EP1029052B1 (en) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
EP1034277B1 (en) 1997-11-26 2012-06-27 Inhibitex, Inc. Extracellular matrix-binding proteins from Staphylococcus aureus
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
JP2002516251A (ja) 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
JP2002521058A (ja) 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
KR100644953B1 (ko) 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
EP1117772B1 (en) 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
EP1165795A2 (en) 1999-03-26 2002-01-02 Provalis UK Limited Streptococcus pneumoniae antigens
ATE325620T1 (de) 1999-06-10 2006-06-15 Medimmune Inc Streptococcus pneumoniae proteine und impfstoffe
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
JP2003530872A (ja) 2000-04-27 2003-10-21 メディミューン，インコーポレイテッド 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US20040091495A1 (en) 2000-07-20 2004-05-13 Lars Bjorck Protein
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1330473A2 (en) 2000-10-26 2003-07-30 Imperial College Innovations Limited Streptococcal genes
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
CA2881980A1 (en) 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
CA2450939C (en) 2001-06-15 2012-11-06 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275120A3 (en) 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
CA2487831A1 (en) 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7818252B2 (en) 2003-02-20 2010-10-19 Gilat Satellite Networks, Ltd Enforcement of network service level agreements
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
JP2007525157A (ja) 2003-04-15 2007-09-06 インターツェル・アクチェンゲゼルシャフト 肺炎連鎖球菌抗原
EP1644389B1 (en) 2003-06-16 2011-01-19 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
JP2007528217A (ja) * 2004-02-18 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
CA2608278A1 (en) 2005-05-12 2006-12-28 Guido Grandi Immunogenic compositions for chlamydia trachomatis
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034881A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
WO2007120362A2 (en) 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
ES2437871T3 (es) 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0616306D0 (en) 2006-08-16 2006-09-27 Novartis Ag Vaccines
EP2491947A3 (en) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccine
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
AU2008247165B2 (en) 2007-05-08 2011-11-03 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
EA018068B1 (ru) * 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
MX344330B (es) 2008-03-24 2016-12-13 4Sc Ag Imidazoquinolinas substituidas novedosas.
EP2303236A4 (en) 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
TWM352127U (en) 2008-08-29 2009-03-01 Bestac Advanced Material Co Ltd Polishing pad
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
WO2010144734A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
US20130259898A1 (en) 2009-11-09 2013-10-03 National Jewish Health Vaccine Composition
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011130379A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
CN104093418A (zh) 2011-09-01 2014-10-08 诺华股份有限公司 金黄色葡萄球菌抗原的含佐剂制剂
LT2822947T (lt) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
CN104582726A (zh) 2012-03-07 2015-04-29 诺华股份有限公司 狂犬病病毒免疫原的含佐剂制剂
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
AU2013229432A1 (en) * 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
US20150258190A1 (en) 2012-10-25 2015-09-17 Novartis Ag Nicotinamide as adjuvant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037355B2 (en) 2015-11-06 2024-07-16 Adjuvance Technologies, Inc. Triterpene saponin analogues
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues

Also Published As

Publication number Publication date
SG178954A1 (en) 2012-04-27
WO2011027222A3 (en) 2011-05-05
CN102844047B (zh) 2017-04-05
CA2772916A1 (en) 2011-03-10
BR112012004806B8 (pt) 2022-10-04
US9950062B2 (en) 2018-04-24
EP2459216B1 (en) 2013-10-30
ES2443952T3 (es) 2014-02-21
JP5988492B2 (ja) 2016-09-07
NZ598654A (en) 2014-05-30
AU2010290896B2 (en) 2014-07-03
WO2011027222A2 (en) 2011-03-10
CN102844047A (zh) 2012-12-26
EP2459216A2 (en) 2012-06-06
MX2012002723A (es) 2012-04-11
JP2013503845A (ja) 2013-02-04
CA2772916C (en) 2019-01-15
DK2459216T3 (da) 2013-12-09
BR112012004806A2 (pt) 2016-11-29
EA026401B1 (ru) 2017-04-28
US20120237546A1 (en) 2012-09-20
AU2010290896A1 (en) 2012-04-05
BR112012004806B1 (pt) 2020-12-29
EA201270356A1 (ru) 2012-09-28

Similar Documents

Publication Publication Date Title
CL2012000585A1 (es) Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante.
AR082686A1 (es) Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos
UY32062A (es) Inhibidores de beta-secretasa
UY32490A (es) Inhibidores de beta-secretasa
AR077629A1 (es) Mimetico de smac
CL2011003192A1 (es) Acido (2s)-3-(2-fluoro-5-(5-fluoro-1h-pirrolo[2,3-b]piridin-3-il)fenilamino)biciclo[2.2.2]octano-2-carboxilico; metodo para prepararlo; composicion farmaceutica que lo comprende; y su uso en el tratamiento de la influenza; metodo para reducir el virus de la influenza in vitro.
MX2008013619A (es) Aumento del titulo para vacunacion en animales.
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
ECSP14028506A (es) Nucleósidos de espirooxetano de uracilo
GT201200158A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
AR082600A1 (es) Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
AR073524A1 (es) Piridopirimidinonas inhibidores de pi3k a y m tor
AR071809A1 (es) Composiciones orales y sus usos
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
UA108378C2 (uk) Спосіб одержання плеуромутилінів
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
AR089269A1 (es) Composiciones para el cuidado oral
AR096705A1 (es) Composición que comprende ácido glutámico-n,n-diacetato (glda), agua y enzima
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
CO6400226A2 (es) Micrólido anti-inflamatorio
CO6241150A2 (es) Procedimiento de preparacion de combretastatina
AR080025A1 (es) Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina